Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
Ms. Korfin’s presentation will include an overview of the company’s corporate strategy and commercial strategy for Omisirge®.
The webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.
About
Omisirge® is a registered trademark of
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the potentially life-saving or curative therapeutic and commercial potential of Omisirge® (omidubicel-onlv), the company’s plans for commercial or strategic partnerships to support the launch of Omisirge. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions including those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005879/en/
Investor and Media Contact:
Orangefiery
media@orangefiery.com
1-818-209-1692
Source: